7 terminated. 7 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Terminated 7 |
| Phase 2 | 2 | Terminated 2 |
Follow Metastatic Solid Tumors: new trials by email Literature Review of Metastatic Solid Tumors trials Research Report on Metastatic Solid Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors INCB177054, Retifanlimab - Solid Tumors, Advanced Solid Tumors | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 9 | 2025-06-30 | 2026-09-02 |
| A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification BGB-53038, Tislelizumab, Cetuximab - Metastatic Solid Tumors, Advanced Non-squamous Non-small-cell Lung Cancer | Phase 1 | Terminated | BeOne Medicines | 47 | 2024-12-13 | 2026-07-08 |
| A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors PF-06939999 dose escalation, PF-06939999 monotherapy, PF-06939999 in combination with docetaxel - Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 | Terminated | Pfizer | 54 | 2019-03-14 | 2025-01-13 |
| Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer INBRX-105 - PDL1x41BB antibody, Pembrolizumab - Metastatic Solid Tumors, Non-small Cell Lung Cancer | Phase 1 | Terminated | Inhibrx Biosciences, Inc | 160 | 2019-01-30 | 2024-10-23 |
| This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors. OBI-888, Globo H IHC Assay - Metastatic Solid Tumors, Locally Advanced Solid Tumors | Phase 1 / Phase 2 | Terminated | OBI Pharma, Inc | 54 | 2018-05-07 | 2024-02-22 |
| MEN1309 I.v. Infusion in Pts With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory NHL Ph I Study MEN1309 - Metastatic Solid Tumors, Relapsed/Refractory Non-Hodgkin Lymphoma | Phase 1 | Terminated | Menarini Group | 28 | 2017-08-28 | 2021-09-28 |
| A Study of DCC-2701 in Participants With Advanced Solid Tumors DCC-2701 tablet - Locally Advanced Tumors, Metastatic Solid Tumors | Phase 1 | Terminated | Deciphera Pharmaceuticals, LLC | 44 | 2014-06-01 | 2018-02-01 |
Adenocarcinoma Of Esophagus (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Head and Neck Neoplasms (1) · Kidney Neoplasms (1) · Lung Neoplasms (1) · Lymphoma, Non-Hodgkin (1) · Melanoma (1) · Nasopharyngeal Carcinoma (1) · Neoplasm Metastasis (1) · Oropharyngeal Neoplasms (1) · Recurrence (1) · Squamous Cell Carcinoma of Head and Neck (1) · Stomach Neoplasms (1)
Neoplasms (2) · Neoplasms by Histologic Type (2) · Adenocarcinoma (1) · Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1) · Carcinoma, Squamous Cell (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Disease Attributes (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Hemic and Lymphatic Diseases (1)
Cetuximab (1) · DCC-2701 (1) · Docetaxel (1) · pembrolizumab (1) · tislelizumab (1)
BeOne Medicines (1) · Deciphera Pharmaceuticals, LLC (1) · Incyte Corporation (1) · Inhibrx Biosciences, Inc (1) · Menarini Group (1) · OBI Pharma, Inc (1) · Pfizer (1)
United States (6) · Australia (1) · Belgium (1) · China (1) · Italy (1) · New Zealand (1) · South Korea (1) · Spain (1) · Taiwan (1) · United Kingdom (1)
Apostolia Tsimberidou, MD, PHD (1) · Oliver Rosen, M.D. (1)